Posted On: 08/20/2014 7:35:43 AM
Post# of 273351
Sunshine Biopharma (SBFM) 0.1100 $SBFM
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Secures Dedicated Space to Commence Global Generic Pharmaceutical Operations
Marketwire - Mon Aug 11, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has secured dedicated space in order to commence operations in the generic pharmaceuticals business as planned. Having a specifically dedicated space is required in order for the Company to be granted a Pharmaceutical Establishment and Export License by Health Canada. Once we secure our Establishment Licensed we will be in a position to sign manufacturing and distribution contracts for sale of generic pharmaceuticals in Canada and elsewhere around the globe. According to various estimates, the annual worldwide market for generic pharmaceuticals which Sunshine Biopharma's Canadian subsidiary is positioning itself to participate in is in excess of $100 billion.
Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and Commercialization Contracts in Canada
Marketwire - Tue Jul 29, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in excess of $100 billion per year.
Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
Marketwire - Mon Jun 09, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company's flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in vitro.
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
Marketwire - Mon Mar 31, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.
Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.
Sunshine Biopharma Begins Construction of Mouse Xenograft Models for Pancreatic Cancer to Advance Adva-27a as a Treatment for This Deadly Form of Cancer
Marketwire - Fri Feb 14, 7:00AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.
Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Business Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Tue Feb 04, 7:04AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer, today announced that it is continuing its efforts to re-domiciling the Company in Canada in order to capitalize on management's belief that by doing so, the Company will generate additional business expansion opportunities and gain access to financing programs available to Canadian corporations. On January 31, 2014, the Company filed an S-4 Registration Statement wherein it is attempting to re-domicile to Canada from Colorado.
Sunshine Biopharma Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound
Marketwire Canada - Tue Jan 21, 7:08AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.
Galectin Shares Rise on IND Filing, is Sunshine Biopharma Next in Line?
ACCESSWIRE - Wed Sep 18, 7:21AM CDT
Drug development is a business that can be a minefield; littered with pieces of failed companies that couldn't manage expenses and compounds that failed to meet expectations. The beauty of biotechnology, though, is a level playing field in which companies can grow robust valuations based upon target indications and assets, even at early stages of development. With initiatives around the world to expedite the regulatory pathway and major pharmaceutical companies hungry for acquisitions, there probably isn't a better time to be looking at some well-positioned up-and-comers in the space.
OTC Daily Alert Stock Watch - Sunshine Biopharma Inc., (OTCQB: SBFM)
WorldStockWire - Wed Sep 11, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Sunshine Biopharma Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab
Marketwire - Mon Aug 26, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its parent company, Advanomics Corporation, has signed a binding agreement to acquire Garmen Laboratories (Laboratoires Garmen Inc.), a Good Manufacturing Practices (GMP) laboratory with 45 employees providing complete pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. A profitable company, Garmen Laboratories is headquartered in a 50,000-square-foot, state-of-the-art facility in Montreal, Canada. With nearly 35 years of industry experience, Garmen delivers an array of solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.
Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million
Marketwire - Mon Aug 12, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its parent company, Advanomics Corporation, has been awarded a second research grant, this time from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, the Company's flagship anticancer drug candidate in development for multidrug resistant cancers. The grant, in the amount of $510,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Secures Dedicated Space to Commence Global Generic Pharmaceutical Operations
Marketwire - Mon Aug 11, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has secured dedicated space in order to commence operations in the generic pharmaceuticals business as planned. Having a specifically dedicated space is required in order for the Company to be granted a Pharmaceutical Establishment and Export License by Health Canada. Once we secure our Establishment Licensed we will be in a position to sign manufacturing and distribution contracts for sale of generic pharmaceuticals in Canada and elsewhere around the globe. According to various estimates, the annual worldwide market for generic pharmaceuticals which Sunshine Biopharma's Canadian subsidiary is positioning itself to participate in is in excess of $100 billion.
Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and Commercialization Contracts in Canada
Marketwire - Tue Jul 29, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in excess of $100 billion per year.
Sunshine Biopharma's Adva-27a Featured in 2014 Worldwide Uterine Cancer Report for Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
Marketwire - Mon Jun 09, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company's flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in vitro.
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
Marketwire - Mon Mar 31, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.
Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.
Sunshine Biopharma Begins Construction of Mouse Xenograft Models for Pancreatic Cancer to Advance Adva-27a as a Treatment for This Deadly Form of Cancer
Marketwire - Fri Feb 14, 7:00AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.
Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Business Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Tue Feb 04, 7:04AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer, today announced that it is continuing its efforts to re-domiciling the Company in Canada in order to capitalize on management's belief that by doing so, the Company will generate additional business expansion opportunities and gain access to financing programs available to Canadian corporations. On January 31, 2014, the Company filed an S-4 Registration Statement wherein it is attempting to re-domicile to Canada from Colorado.
Sunshine Biopharma Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound
Marketwire Canada - Tue Jan 21, 7:08AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.
Galectin Shares Rise on IND Filing, is Sunshine Biopharma Next in Line?
ACCESSWIRE - Wed Sep 18, 7:21AM CDT
Drug development is a business that can be a minefield; littered with pieces of failed companies that couldn't manage expenses and compounds that failed to meet expectations. The beauty of biotechnology, though, is a level playing field in which companies can grow robust valuations based upon target indications and assets, even at early stages of development. With initiatives around the world to expedite the regulatory pathway and major pharmaceutical companies hungry for acquisitions, there probably isn't a better time to be looking at some well-positioned up-and-comers in the space.
OTC Daily Alert Stock Watch - Sunshine Biopharma Inc., (OTCQB: SBFM)
WorldStockWire - Wed Sep 11, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Sunshine Biopharma Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab
Marketwire - Mon Aug 26, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its parent company, Advanomics Corporation, has signed a binding agreement to acquire Garmen Laboratories (Laboratoires Garmen Inc.), a Good Manufacturing Practices (GMP) laboratory with 45 employees providing complete pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. A profitable company, Garmen Laboratories is headquartered in a 50,000-square-foot, state-of-the-art facility in Montreal, Canada. With nearly 35 years of industry experience, Garmen delivers an array of solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.
Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million
Marketwire - Mon Aug 12, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its parent company, Advanomics Corporation, has been awarded a second research grant, this time from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, the Company's flagship anticancer drug candidate in development for multidrug resistant cancers. The grant, in the amount of $510,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
(0)
(0)
